Agenus Inc.

NasdaqCM:AGEN 株式レポート

時価総額：US$312.4m

Agenus 過去の業績

過去 基準チェック /26

Agenusは10%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで34.1%毎年増加している。売上は減少しており、年平均16.1%の割合である。

主要情報

9.96%

収益成長率

18.59%

EPS成長率

Biotechs 業界の成長17.04%
収益成長率-16.13%
株主資本利益率n/a
ネット・マージン69.18%
前回の決算情報30 Jun 2026

最近の業績更新

Recent updates

ナラティブ更新 • Aug 15

AGEN: Refocused Colorectal Cancer Pipeline And Funding Will Support Future Upside

Agenus sees its analyst fair value estimate move from $30.00 to $19.50 as analysts recalibrate long term assumptions on revenue growth, profitability and future P/E, following recent price target changes related to financing plans and the refocused pipeline. Analyst Commentary Recent Street research on Agenus highlights a mix of optimism about the refocused pipeline and caution around financing and execution.
ナラティブ更新 • Jul 31

AGEN: Refocused Colon Cancer Program And New Funding Will Drive Upside

Agenus is in focus after analysts lifted their price target to $14 from $8, citing a revised view on fair value, updated growth and margin assumptions, and a higher future P/E multiple following recent research that highlights the company’s refocused oncology pipeline and $340M private placement. Analyst Commentary on Agenus Recent research on Agenus highlights a mix of optimism around the oncology pipeline and the US$340M private placement, alongside some clear areas where analysts see meaningful execution and valuation risks.
ナラティブ更新 • Jul 13

AGEN: Neoadjuvant Colorectal Cancer Focus And Funding Will Drive Bullish Reassessment

Agenus' analyst price target has been reset from $15.50 to $30.00. Analysts point to the company's refocus on botensilimab and balstilimab in neoadjuvant microsatellite stable colorectal cancer, as well as the recently announced $340.0m private placement, as key drivers of their updated view.
ナラティブ更新 • Jun 23

AGEN: Late-Stage Cancer Pipeline And Access Programs Will Drive Future Upside

Analysts have revised their price target on Agenus to reflect a lower assumed future P/E of 24.80x, down from 34.01x, alongside updated views on revenue growth and profit margins that together temper growth expectations while assuming a stronger profitability profile. What’s in the News for Agenus Agenus is advancing its botensilimab plus balstilimab program with new retrospective data using Noetik’s AI based TARIO-2 model to analyze routine H&E tumor images and identify spatial tumor microenvironment patterns linked with clinical outcomes in solid tumors, including microsatellite stable metastatic colorectal cancer, ovarian cancer, and sarcomas, with results to be presented at the 2026 ASCO Annual Meeting.
ナラティブ更新 • Jun 08

AGEN: Phase 3 Colorectal Cancer Trial Will Support Bullish Reassessment

Analyst price targets for Agenus have been reaffirmed at $15.50, with modest adjustments to the discount rate, revenue growth assumptions, profit margin and forward P/E reflecting analysts' updated view of the stock's risk profile and earnings potential. What's in the News Agenus is advancing its botensilimab plus balstilimab (BOT+BAL) program with multiple data disclosures, including new Phase 2 results in advanced cutaneous melanoma and published Phase 1b data in treatment refractory hepatocellular carcinoma.
ナラティブ更新 • May 24

AGEN: Phase 3 Colorectal Cancer Trial Will Drive Bullish Reassessment

Analysts now set a higher price target for Agenus, moving their fair value estimate from $12.33 to $15.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Phase 2 data from the C-800-23 study in advanced cutaneous melanoma showed a 22% confirmed objective response rate for botensilimab plus balstilimab, with median overall survival of 16.6 months and a 42% 2 year overall survival rate in the overall cohort, and no treatment related deaths reported (Key Developments).
ナラティブ更新 • May 04

AGEN: Late Stage Cancer Data And Access Programs Will Drive Future Upside

Analysts have reduced their price targets on Agenus by $8.00 after updating their assumptions for revenue growth, profit margins, and future P/E levels to reflect a more conservative view of the stock’s valuation inputs. What's in the News Agenus is presenting four botensilimab and balstilimab abstracts at the 2026 ASCO Annual Meeting, including first Phase 2 data in advanced cutaneous melanoma and a trial-in-progress update on the Phase 3 CO.33/BATTMAN colorectal cancer study (Key Developments).
ナラティブ更新 • Apr 20

AGEN: Late Stage Gastrointestinal Cancer Data Will Drive Future Upside

Analysts have nudged their price target on Agenus higher to $8.00, reflecting updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Agenus reported Phase II data from a Memorial Sloan Kettering trial combining botensilimab, balstilimab, agenT-797, ramucirumab, and paclitaxel in advanced PD-1 refractory gastroesophageal adenocarcinoma, with a 77% disease control rate in 17 patients and a subset showing survival beyond 20 months (AACR Annual Meeting 2026).
ナラティブ更新 • Apr 04

AGEN: Expanded Late-Stage Trials And Access Programs Will Drive Future Upside

Analysts have raised their price target on Agenus from $6.00 to $8.00. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and a higher future P/E of 28.67x compared with 19.01x previously.
ナラティブ更新 • Aug 17

Advanced Immuno-Oncology Therapies Will Reshape Future Cancer Care

The notable upward revision in Agenus’s fair value target is primarily driven by significant improvements in net profit margin and a modest increase in forecasted revenue growth, resulting in a consensus analyst price target increase from $11.00 to $12.33. What's in the News Agenus' botensilimab and balstilimab immunotherapy programs continue to show promising clinical progress, with new survival data and presentations at major oncology congresses, including a 42% two-year survival rate and 21-month median OS in immunotherapy-resistant MSS metastatic colorectal cancer.
User avatar
新しいナラティブ • Apr 08

BOT/BAL Trials And Cost Reductions Will Shape Future Advances

Strategic cost reduction and asset monetization aim to strengthen financials and fund key projects like BOT/BAL, enhancing potential revenues and earnings.
Seeking Alpha • Jul 24

Agenus: Novel Drugs That Just Are Not Novel

Summary Agenus is a small biotech company focused on developing cancer treatments, with a history of poor stock performance and financial struggles. The company's primary assets in its pipeline are Botensilimab and Balstilimab, which have shown limited efficacy in pre-clinical and clinical trials. Recent FDA meeting and phase 2 metastatic colorectal cancer data plummeted AGEN stock 60%, due to discouragement to file for accelerated approval. Further funding is likely to be required soon, considering high cash burn rates and the upcoming phase 3 trial in mCRC. Read the full article on Seeking Alpha
分析記事 • May 21

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

Agenus Inc. ( NASDAQ:AGEN ) shareholders are no doubt pleased to see that the share price has bounced 102% in the last...
分析記事 • May 09

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

Shareholders might have noticed that Agenus Inc. ( NASDAQ:AGEN ) filed its quarterly result this time last week. The...

収支内訳

Agenus の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:AGEN 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 26133923876
31 Mar 26124644667
31 Dec 2511405476
30 Sep 25107-3563144
30 Jun 25102-16669144
31 Mar 25100-19171165
31 Dec 24103-22772144
30 Sep 24160-228720
30 Jun 24160-224740
31 Mar 24161-240770
31 Dec 23156-24679228
30 Sep 23101-271830
30 Jun 2399-263820
31 Mar 2395-240800
31 Dec 2298-220810
30 Sep 2290-215780
30 Jun 2232018810
31 Mar 22310-19790
31 Dec 21296-24760
30 Sep 213074740
30 Jun 2169-226670
31 Mar 2185-190650
31 Dec 2088-181590
30 Sep 2091-174520
30 Jun 2097-168490
31 Mar 2085-171460
31 Dec 19150-108460
30 Sep 19122-126430
30 Jun 19115-113410
31 Mar 19115-87390
31 Dec 1837-160370
30 Sep 1839-147370
30 Jun 1829-151360
31 Mar 1818-158350
31 Dec 1743-121340
30 Sep 1740-112330
30 Jun 1741-116330
31 Mar 1744-113320
31 Dec 1623-127330
30 Sep 1625-117330
30 Jun 1627-89310
31 Mar 1627-101320
31 Dec 1525-88280
30 Sep 1519-98250

質の高い収益: AGENには$112.8M } という大きな 一回限りの 利益があり、過去 12 か月の財務実績が30th June, 2026に影響を及ぼしています。

利益率の向上: AGEN過去に利益を上げました。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: AGEN過去 5 年間で収益を上げており、収益は年間10%増加しています。

成長の加速: AGENは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: AGEN昨年収益を上げたため、昨年の収益成長をBiotechs業界 ( 64.6% ) と比較することは困難です。

株主資本利益率

高いROE: AGENの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/09/14 18:59
終値2026/09/14 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Agenus Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7

アナリスト機関
Mayank MamtaniB. Riley Securities, Inc.
Michael KingCitizens JMP Securities, LLC
Emily BodnarH.C. Wainwright & Co.